{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T12:54:54Z","timestamp":1793019294628,"version":"4.5.0"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,7,25]],"date-time":"2022-07-25T00:00:00Z","timestamp":1658707200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Baricitinib is a Janus kinase (JAK) 1 and 2 inhibitor approved for treating rheumatoid arthritis (RA). The JAK\/STAT system is essential in the intracellular signaling of different cytokines and in the activation process of the monocyte lineage. This study verifies the effects of baricitinib on STAT phosphorylation in monocytes of RA patients and evaluates the correlation between STAT phosphorylation and response to therapy. We evaluated the disease activity of patients (DAS28CRP) at baseline (T0) and after 4 and 12 weeks (T1\u2013T3) of treatment with baricitinib, dividing them into responders (n = 7) and non-responders (n = 7) based on the reduction of DAS28CRP between T0 and T1 of at least 1.2 points. Through flow cytometry, STAT1 phosphorylation was analyzed at T0\/T1\/T3 in monocytes, at basal conditions and after IL2, IFN\u03b1, and IL6 stimulation. We showed that monocyte frequency decreased from T0 to T1 only in responders. Regarding the phosphorylation of STAT1, we observed a tendency for higher basal pSTAT1 in monocytes of non-responder patients and, after 4 weeks, a significant reduction of cytokine-induced pSTAT1 in monocytes of responders compared with non-responders. The single IFN\u03b1 stimulation only partially recapitulated the differences in STAT1 phosphorylation between the two patient subgroups. Finally, responders showed an increased IFN signature at baseline compared with non-responders. These results may suggest that monocyte frequency and STAT1 phosphorylation in circulating monocytes could represent early markers of response to baricitinib therapy.<\/jats:p>","DOI":"10.3389\/fimmu.2022.932240","type":"journal-article","created":{"date-parts":[[2022,7,25]],"date-time":"2022-07-25T06:56:50Z","timestamp":1658732210000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":23,"title":["Baricitinib therapy response in rheumatoid arthritis patients associates to STAT1 phosphorylation in monocytes"],"prefix":"10.3389","volume":"13","author":[{"given":"Gloria","family":"Tucci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Garufi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilenia","family":"Pacella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Zagaglioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Pinzon Grimaldos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fulvia","family":"Ceccarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Conti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca Romana","family":"Spinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Piconese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,7,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)30173-8","article-title":"Rheumatoid arthritis","volume":"388","author":"Smolen","year":"2016","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.3390\/cells10081860","article-title":"Tuning monocytes and macrophages for personalized therapy and diagnostic challenge in rheumatoid arthritis","volume":"10","author":"Roszkowski","year":"2021","journal-title":"Cells"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/nri3712","article-title":"Dendritic cells, monocytes and macrophages: a unified nomenclature based on ontogeny","volume":"14","author":"Guilliams","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.790122","article-title":"Molecular and cellular heterogeneity in rheumatoid arthritis: mechanisms and clinical implications","volume":"12","author":"Zhao","year":"2021","journal-title":"Front Immunol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"R175","DOI":"10.1186\/ar3928","article-title":"Monocyte populations as markers of response to adalimumab plus MTX in rheumatoid arthritis","volume":"14","author":"Chara","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2020.8982","article-title":"JAK\/STAT pathway in pathology of rheumatoid arthritis (Review)","volume":"20","author":"Ciobanu","year":"2020","journal-title":"Exp Ther Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"108793","DOI":"10.1016\/j.clim.2021.108793","article-title":"Recent advances on signaling pathways and their inhibitors in rheumatoid arthritis","volume":"230","author":"Liu","year":"2021","journal-title":"Clin Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex426","article-title":"Targeted inhibition of janus kinases abates interfon gamma-induced invasive behaviour of fibroblast-like synoviocytes","volume":"57","author":"Karonitsch","year":"2018","journal-title":"Rheumatol (Oxford)"},{"key":"B9","doi-asserted-by":"publisher","first-page":"173238","DOI":"10.1016\/j.ejphar.2020.173238","article-title":"Role of JAK-STAT signaling in the pathogenic behavior of fibroblast-like synoviocytes in rheumatoid arthritis: Effect of the novel JAK inhibitor peficitinib","volume":"882","author":"Emori","year":"2020","journal-title":"Eur J Pharmacol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-eular.1801","article-title":"Jak inhibitors \u2013 baricitinib and tofacitinib \u2013 modulate the in vitro inflammatory and alternative polarizations of macrophages","volume":"78","author":"Magnol","year":"2019","journal-title":"Ann Rheumatic Diseases"},{"key":"B11","doi-asserted-by":"publisher","first-page":"114103","DOI":"10.1016\/j.bcp.2020.114103","article-title":"Combined anti-fibrotic and anti-inflammatory properties of JAK-inhibitors on macrophages in vitro and in vivo: Perspectives for scleroderma-associated interstitial lung disease","volume":"178","author":"Lescoat","year":"2020","journal-title":"Biochem Pharmacol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"561","DOI":"10.3390\/cells8060561","article-title":"Peficitinib inhibits the chemotactic activity of monocytes via proinflammatory cytokine production in rheumatoid arthritis fibroblast-like synoviocytes","volume":"8","author":"Ikari","year":"2019","journal-title":"Cells"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/art.27584","article-title":"2010 Rheumatoid arthritis classification criteria: an American college of Rheumatology\/European league against rheumatism collaborative initiative","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheum"},{"key":"B14","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1002\/art.1780390105","article-title":"Development and validation of the european league against rheumatism response criteria for rheumatoid arthritis. comparison with the preliminary american college of rheumatology and the world health organization\/international league against rheumatism criteria","volume":"39","author":"van Gestel","year":"1996","journal-title":"Arthritis Rheumatol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208001","article-title":"Increased pretreatment serum IFN-beta\/alpha ratio predicts non-response to tumour necrosis factor alpha inhibition in rheumatoid arthritis","volume":"75","author":"Wampler Muskardin","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1221","article-title":"ISG15 protects human tregs from interferon alpha-induced contraction in a cell-intrinsic fashion","volume":"9","author":"Pacella","year":"2020","journal-title":"Clin Transl Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/art.33418","article-title":"The CD14(bright) CD16+ monocyte subset is expanded in rheumatoid arthritis and promotes expansion of the Th17 cell population","volume":"64","author":"Rossol","year":"2012","journal-title":"Arthritis Rheumatol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2249.1998.00617.x","article-title":"Selective depletion of CD14+ CD16+ monocytes by glucocorticoid therapy","volume":"112","author":"Fingerle-Rowson","year":"1998","journal-title":"Clin Exp Immunol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2690402","DOI":"10.1155\/2017\/2690402","article-title":"Effect of tumor necrosis factor inhibitor therapy on osteoclasts precursors in rheumatoid arthritis","volume":"2017","author":"Perpetuo","year":"2017","journal-title":"BioMed Res Int"},{"key":"B20","doi-asserted-by":"publisher","first-page":"291","DOI":"10.3390\/ijms20020291","article-title":"TNF-alpha inhibitors decrease classical CD14(hi)CD16- monocyte subsets in highly active, conventional treatment refractory rheumatoid arthritis and ankylosing spondylitis","volume":"20","author":"Batko","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B21","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13075-016-1216-6","article-title":"CD14(bright)CD16+ intermediate monocytes are induced by interleukin-10 and positively correlate with disease activity in rheumatoid arthritis","volume":"19","author":"Tsukamoto","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2016.03.034","article-title":"Relation among anti-rheumatic drug therapy, CD14(+)CD16(+) blood monocytes and disease activity markers (DAS28 and US7 scores) in rheumatoid arthritis: A pilot study","volume":"107","author":"Amoruso","year":"2016","journal-title":"Pharmacol Res"},{"key":"B23","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1186\/ar2883","article-title":"Genetic associations in type I interferon related pathways with autoimmunity","author":"Delgado-Vega","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"B24","doi-asserted-by":"publisher","first-page":"196","DOI":"10.3109\/08916930903510872","article-title":"Type I interferons in systemic autoimmunity","volume":"43","author":"Sozzani","year":"2010","journal-title":"Autoimmunity"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.15.1.749","article-title":"Cellular responses to interferon-gamma","volume":"15","author":"Boehm","year":"1997","journal-title":"Annu Rev Immunol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1146\/annurev.immunol.16.1.293","article-title":"Jaks and STATs: biological implications","volume":"16","author":"Leonard","year":"1998","journal-title":"Annu Rev Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1136\/ard.59.4.263","article-title":"Differential Th1\/Th2 cytokine patterns in chronic arthritis: interferon gamma is highly expressed in synovium of rheumatoid arthritis compared with seronegative spondyloarthropathies","volume":"59","author":"Canete","year":"2000","journal-title":"Ann Rheum Dis"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/ni1576","article-title":"TNF activates an IRF1-dependent autocrine loop leading to sustained expression of chemokines and STAT1-dependent type I interferon-response genes","volume":"9","author":"Yarilina","year":"2008","journal-title":"Nat Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.050385","article-title":"Changes in synovial tissue jak-STAT expression in rheumatoid arthritis in response to successful DMARD treatment","volume":"65","author":"Walker","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"B30","doi-asserted-by":"publisher","first-page":"8830","DOI":"10.1038\/s41598-020-63757-3","article-title":"Novel biomarkers of a peripheral blood interferon signature associated with drug-naive early arthritis patients distinguish persistent from self-limiting disease course","volume":"10","author":"Seyhan","year":"2020","journal-title":"Sci Rep"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-020-08798-2","article-title":"Type I interferons in the pathogenesis and treatment of autoimmune diseases","volume":"59","author":"Jiang","year":"2020","journal-title":"Clin Rev Allergy Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00285","article-title":"Type I interferon gene response is increased in early and established rheumatoid arthritis and correlates with autoantibody production","volume":"8","author":"Castaneda-Delgado","year":"2017","journal-title":"Front Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-018-0020-5","article-title":"ISG15 in antiviral immunity and beyond","volume":"16","author":"Perng","year":"2018","journal-title":"Nat Rev Microbiol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2020-000424","article-title":"Baricitinib-associated changes in global gene expression during a 24-week phase II clinical systemic lupus erythematosus trial implicates a mechanism of action through multiple immune-related pathways","volume":"7","author":"Dorner","year":"2020","journal-title":"Lupus Sci Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-219012","article-title":"JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib","volume":"80","author":"Traves","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1002\/art.33347","article-title":"Interferon signals and monocytic sensitization of the interferon-gamma signaling pathway in the peripheral blood of patients with rheumatoid arthritis","volume":"64","author":"Karonitsch","year":"2012","journal-title":"Arthritis Rheumatol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez526","article-title":"In vitro pharmacological effects of peficitinib on lymphocyte activation: a potential treatment for systemic sclerosis with JAK inhibitors","volume":"59","author":"Kitanaga","year":"2020","journal-title":"Rheumatol (Oxford)"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0167975","article-title":"STAT6 and STAT1 pathway activation in circulating lymphocytes and monocytes as predictor of treatment response in rheumatoid arthritis","volume":"11","author":"Kuuliala","year":"2016","journal-title":"PloS One"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1007\/s11010-022-04444-x","article-title":"Tofacitinib enhances IGF1 via inhibiting STAT6 transcriptionally activated-miR-425-5p to ameliorate inflammation in RA-FLS","author":"Liu","year":"2022","journal-title":"Mol Cell Biochem"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.3390\/biomedicines9101413","article-title":"Targeting of janus kinases limits pro-inflammatory but also immunosuppressive circuits in the crosstalk between synovial fibroblasts and lymphocytes","volume":"9","author":"Yao","year":"2021","journal-title":"Biomedicines"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1002\/art.37691","article-title":"Regulation of inflammatory responses in tumor necrosis factor-activated and rheumatoid arthritis synovial macrophages by JAK inhibitors","volume":"64","author":"Yarilina","year":"2012","journal-title":"Arthritis Rheumatol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-206028","article-title":"The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis","volume":"74","author":"Boyle","year":"2015","journal-title":"Ann Rheum Dis"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.932240\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,25]],"date-time":"2022-07-25T06:56:53Z","timestamp":1658732213000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.932240\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,25]]},"references-count":42,"alternative-id":["10.3389\/fimmu.2022.932240"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.932240","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,25]]},"article-number":"932240"}}